[ad_1] Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. However, the injection did not cause lower rates of brain swelling and bleeding, which are Leqembi’s most concerning…
[ad_1] Jim Cramer ran through all 35 Club stocks during our September Monthly Meeting on Thursday. [ad_2] Source link
[ad_1] In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company’s oral drug zuranolone…
[ad_1] As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs, blood tests and other diagnostics, fueling increased demand for these important tools. In earnings calls this week, both GE Healthcare and Quest Diagnostics made references to the potential opportunity here, although neither company put any specific estimates behind their…
[ad_1] A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen on Tuesday said it expects to cut approximately 1,000 jobs, or about 11% of its workforce, to save costs as the biotech company prepares to launch its newly approved Alzheimer’s drug Leqembi. It’s the latest round of layoffs after Biogen slashed nearly 900…
[ad_1] Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Monday said it applied for full U.S. Food and Drug Administration approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year. Eli Lilly…
[ad_1] The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease. Leqembi is the only drug on…
[ad_1] Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan at MedStar Georgetown University Hospital in Washington, DC on June 20, 2023. Michael Robinson Chávez | The Washington Post | Getty Images Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could…
[ad_1] The Food and Drug Administration on Thursday fully approved the Alzheimer’s treatment Leqembi, a pivotal decision that will expand access to the expensive drug for older Americans. Medicare announced shortly after the FDA approval that it is now covering the antibody treatment for patients enrolled in the insurance program for seniors, though several conditions…
[ad_1] [The stream is scheduled to begin at 10 a.m. ET. Please refresh the page if you don’t see a player above at that time.] A panel of independent advisors to the Food and Drug Administration is meeting Friday to make a recommendation on whether the Alzheimer’s drug Leqembi, made by Eisai and Biogen, should…
